Introduction:
Pharma stock secured a partnership with CVS Caremark to include type 2 diabetes drugs Zituvio, Zituvimet, and Zituvimet XR in its formulary, enhancing patient access to affordable, high-quality medications in the US market starting January 2025.
Share Price movement of Zydus Lifesciences:
On January 7, 2025, Zydus Lifesciences Ltd opened at ₹970.00, hitting an intraday high of ₹1,014.00 and a low of ₹969.90. The current price is ₹999.30, up 3.94% from the previous close of ₹961.45, with a market cap of ₹1,00,552.96 crore.
Zydus Lifesciences share price rise:
Zydus Lifesciences Ltd announced an agreement with CVS Caremark to include ZituvioTM, ZituvimetTM, and ZituvimetTM XR (Sitagliptin | Sitagliptin and Metformin Hydrochloride) in its template formulary starting January 1, 2025. These products target type 2 diabetes management.
The Zituvio range, approved by the USFDA under the 505(b)(2) route, includes DPP-4 inhibitor sitagliptin and biguanide metformin hydrochloride. These medications, combined with diet and exercise, aim to improve glycemic control in adults with type 2 diabetes mellitus.
Punit Patel, President & CEO of Zydus Pharmaceuticals USA, emphasized the partnership enhances access to high-quality medications while reducing costs. The collaboration reinforces Zydus’ commitment to strengthening its portfolio of differentiated products in the US market.
Also Read: Infra stock jumps 4% after receiving order worth ₹1,391 Cr from NHAI
Recent news About Zydus Lifesciences :
On January 3, 2025, Zydus Lifesciences Limited announced the appointment of Mr. Vikram Shukla as President-Parenteral Operations and designated him as Senior Management Personnel, following the Board’s approval based on the Nomination and Remuneration Committee’s recommendation.
Stock performance of Zydus Lifesciences for Period of 1 week, 6 months and 1 year:
Zydus Lifesciences’ stock showed varied performance over different periods. It declined by 1.05% over the past week and 17.4% over six months. However, it achieved a notable 35.3% return over the past year, reflecting strong long-term growth potential.
Also Read: PSU stock jumps after company’s board approves Maharashtra Natural Gas
Shareholding pattern of Zydus Lifesciences:
| All values in % | Sep-24 | Jun-24 | Mar-24 |
| Promoters | 74.98 | 74.98 | 74.98 |
| FII | 7.52 | 5.59 | 5.72 |
| DII | 10.64 | 12.63 | 12.62 |
| Retail & others | 6.85 | 6.81 | 6.66 |
About Zydus Lifesciences:
Zydus Lifesciences is a leading healthcare company specializing in pharmaceuticals, biologics, and wellness products. With a focus on innovation and patient-centric solutions, it addresses global healthcare challenges through its diverse portfolio and robust research and development capabilities.
Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time The securities quoted are exemplary and are not recommendatory.
